本公司及董事会全体成员保证公告内容与信息披露义务人提供的信息一致。 特别提示： 天康生物 证券代码：002100 证券简称：天康生物 公告编号：2025-033 天康生物股份有限公司 关于控股股东增持公司股份计划实施完成 暨增持股份达到 1%的公告 公司控股股东新疆生产建设兵团国有资产经营有限责任公司保证向本公司提 供的信息内容真实、准确、完整，没有虚假记载、误导性陈述或重大遗漏。 增持计划：天康生物股份有限公司（以下简称"公司"）控股股东新疆生 产建设兵团国有资产经营有限责任公司（以下简称"兵团国资公司"）计划自 2024 年 11 月 20 日起 6 个月内增持本公司股份，计划增持金额不少于人民币 10,000 万 元，不超过人民币 20,000 万元，本次增持不设定价格区间。 增持进展：截至 2025 年 5 月 19 日暨本次增持计划实施期限届满，兵团国 资公司通过深圳证券交易所交易系统以集中竞价方式增持公司股份 24,321,903 股，占公司总股本的 1.78%，增持金额为 159,890,689.93 元，达到增持计划下限 金额，且未超上限，本次增持计划实施完毕。本次增持后，兵团国资公司持有公 ...

Core Viewpoint - The company TianKang Biological (002100) announced that its controlling shareholder, Xinjiang Production and Construction Corps State-owned Assets Management Co., Ltd., has completed its shareholding increase plan, acquiring a total of 24.32 million shares, which represents 1.78% of the company's total share capital, for an amount of 160 million yuan [1] Summary by Relevant Categories Shareholding Increase - The controlling shareholder increased its stake by acquiring 24.32 million shares through the Shenzhen Stock Exchange, representing 1.78% of the total share capital [1] - The total amount spent on this share acquisition was 160 million yuan [1] Current Shareholding Structure - After the completion of the shareholding increase, the state-owned assets management company holds a total of 319 million shares in the company, which corresponds to a holding ratio of 23.36% [1]

天康生物 2024 年年度股东大会决议公告 本公司及董事会全体成员保证公告内容的真实、准确和完整，没有虚假记载、 误导性陈述或者重大遗漏。 重要提示： 1、本次股东大会无增加、变更、否决提案的情况； 2、本次股东大会未涉及变更以往股东大会已通过决议的情况。 一、 会议召开和出席情况 （一）会议召开时间 证券代码：002100 证券简称：天康生物 公告编号：2025-032 天康生物股份有限公司 天康生物 现场会议时间：2025 年 5 月 20 日上午 11：00 时 网络投票时间：2025 年 5 月 20 日，其中，通过深圳证券交易所交易系统进 行网络投票的具体时间为 2025 年 5 月 20 日上午 9:15—9:25，9:30—11:30 和下 午 13:00-15:00；通过深圳证券交易所互联网投票系统进行网络投票的具体时间 为 2025 年 5 月 20 日上午 9：15 至下午 15:00 任意时间。 （二）会议召开地点：新疆乌鲁木齐市高新区长春南路 528 号天康企业大 厦 11 楼公司 4 号会议室。 （三）会议召开方式：现场投票与网络投票相结合的方式。 （四）会议召集人：公司董事会 （五 ...

天康生物 2024 年年度股东大会法律意见书 新疆星河井然律师事务所 关于天康生物股份有限公司 为出具本法律意见书，本所律师对公司本次会议所涉及的有关事项进 行了审查，查阅了本所律师认为出具本法律意见书所必须查阅的文件，并 对有关问题进行了必要的核查和验证。 本法律意见书仅供本次会议见证之目的使用，不得用作其他任何目的。 本所律师同意将本法律意见书随公司本次会议决议一起公告，并依法 对本法律意见书承担相应的责任。 本所律师根据相关法律、法规和规范性文件的要求，按照律师行业公 认的业务标准、道德规范和勤勉尽责精神，出具法律意见如下： 2024 年年度股东大会之 法律意见书 星河证股字[2025]第 004 号 致：天康生物股份有限公司 新疆星河井然律师事务所（以下简称"本所"）接受天康生物股份有 限公司（以下简称"公司"）委托，指派律师出席公司 2024 年年度股东 大会（以下简称"本次会议"），并根据《中华人民共和国证券法》（以 下简称"《证券法》"）、《中华人民共和国公司法》（以下简称"《公 司法》"）、《上市公司股东大会规则》（以下简称"《规则》"）、《深 圳证券交易所股票上市规则》（以下简称"《上市规则 ...

Core Viewpoint - The animal vaccine sector has shown a significant increase, with a 4.00% rise, ranking third among concept sectors, driven by notable gains in several stocks [1][2]. Group 1: Sector Performance - As of May 20, the animal vaccine concept increased by 4.00%, with 19 stocks rising, including *ST Xianfeng, which hit the daily limit, and others like Kexing Pharmaceutical, Ruipu Biological, and Kanghua Biological, which rose by 15.56%, 8.41%, and 6.70% respectively [1][2]. - The animal vaccine sector was among the top-performing sectors, alongside cultivated diamonds and pet economy, which rose by 4.10% and 4.08% respectively [2]. Group 2: Capital Inflow - The animal vaccine sector saw a net inflow of 67 million yuan, with 13 stocks receiving net inflows, and 6 stocks attracting over 10 million yuan in net inflows [2]. - Jinhe Biological led the net inflow with 36.88 million yuan, followed by Kexing Pharmaceutical, Dabeinong, and Plk, which received net inflows of 15.38 million yuan, 13.79 million yuan, and 13.60 million yuan respectively [2][3]. Group 3: Capital Flow Ratios - Stocks such as *ST Xianfeng, Kexing Pharmaceutical, and KQ Biotech had the highest net inflow ratios, at 14.17%, 6.56%, and 5.52% respectively [3]. - The top stocks in terms of capital inflow included Jinhe Biological with a turnover rate of 18.22% and a daily increase of 4.40%, and Kexing Pharmaceutical with a turnover rate of 3.46% and a daily increase of 15.56% [3][4].

Group 1 - The China Livestock Breeding Index (930707) has shown a slight increase of 0.18% as of May 19, 2025, with notable gains in stocks such as Xiangjia Co., Ltd. (002982) up by 6.62% and Yike Foods (301116) up by 1.73% [1] - The recent outbreak of highly pathogenic avian influenza in Brazil has led to a suspension of poultry imports from Brazil by Mexico, impacting the poultry market [1] - A report from Guojin Securities indicates that the price of white feather chickens has rebounded due to previous price drops and improved consumer demand, while the supply of breeding chickens has significantly decreased year-on-year [1] Group 2 - The macroeconomic policy adjustments are expected to gradually boost consumer demand, leading to an increase in poultry product consumption and a higher proportion of high-end products [2] - The dairy industry is anticipated to stabilize and recover in the second half of 2025, with ongoing low prices for raw milk and an acceleration in industry capacity reduction [2] - The top ten weighted stocks in the China Livestock Breeding Index account for 69.38% of the index, with companies like Haida Group (002311) and Muyuan Foods (002714) being the most significant contributors [3]

本次活动将采用网络远程的方式举行，投资者可登录"全景路演"网站 （http://rs.p5w.net），或关注微信公众号：全景财经，或下载全景路演 APP， 参与本次互动交流，活动时间为 2025 年 5 月 23 日（周五）15:00-17:30。届时公 司高管将在线就公司 2024 年度业绩、公司治理、发展战略、经营状况、融资计划 和可持续发展等投资者关心的问题，与投资者进行沟通与交流，欢迎广大投资者 踊跃参与！ 特此公告。 天康生物 证券代码：002100 证券简称：天康生物 公告编号：2025-031 天康生物股份有限公司 关于参加新疆辖区上市公司 2025 年投资者 网上集体接待日活动的公告 本公司及董事会全体成员保证信息披露的内容真实、准确和完整，没有虚假 记载、误导性陈述或者重大遗漏。 为进一步加强与投资者的互动交流，天康生物股份有限公司（以下简称"公 司"）将参加由新疆上市公司协会根据新疆证监局工作部署，联合深圳市全景网 络有限公司举办的"2025 年新疆辖区上市公司投资者网上集体接待日活动"，现 将相关事项公告如下： 天康生物股份有限公司董事会 2025 年 5 月 17 日 ...

Investment Rating - The industry investment rating is "Positive" (maintained) [2] Core Viewpoints - In April 2025, the national average selling price of live pigs was 14.80 yuan/kg, with a month-on-month increase of 1.33% and a year-on-year decrease of 1.95% [6][18] - The supply gap in May is expected to lead to a further increase in the price center of live pigs, driven by limited increases in supply and improving demand [6][18] - The average weight of pigs sold is expected to gradually decline, but the narrowing price difference between different grades of pigs will have limited pressure on prices [7][22] Summary by Sections Industry Overview - April saw a non-seasonal increase in pig prices, with expectations for further price increases in May due to supply constraints and improving demand [6][18] - The average price of live pigs in April was 14.80 yuan/kg, with a month-on-month increase of 1.33% [6][18] - The slaughter volume in April was 4.213 million heads, a month-on-month decrease of 4.54% but a year-on-year increase of 6.76% [6][18] Supply and Demand Dynamics - The supply of pigs is expected to be limited in May due to previous culling and disease impacts, while demand for pork is showing marginal improvement [6][18] - The planned output for May is expected to increase by 1.98% compared to actual output in April [6][18] Profitability and Market Performance - The average profit for self-bred pigs in April was 69.44 yuan/head, a month-on-month increase of 63.63% [8][26] - The number of breeding sows in April increased by 0.96% month-on-month [8][26] - The price of 15kg piglets reached 630 yuan/head, indicating a high price level during the replenishment season [8][26] Company Performance - In April, 12 listed pig farming companies collectively sold 16.2368 million pigs, a year-on-year increase of 37.22% [9][28] - Major companies such as Muyuan Foods and Wens Foodstuffs reported significant year-on-year increases in sales volume [9][28] - The average selling prices varied among companies, with some experiencing increases while others saw declines [9][35]

Group 1: Business Performance - In 2024, the company's feed business sales volume increased by 0.87%, while the pig farming business saw a 7.55% increase in annual output, reaching 3.0285 million pigs [2][3] - The average selling price of pigs increased by 10.5% compared to the previous year, leading to a higher revenue share from pig farming [2][3] - The company plans to sell 2.9 million tons of feed and aims for a pig output of 3.5 to 4 million heads in 2025 [2][3] Group 2: Research and Development - The company has obtained 28 national new veterinary drug certificates, focusing on improving pig breeding quality and feed formulation [3][5] - Significant R&D achievements include the development of a gene-engineered inactivated vaccine for swine fever, which is a first in the country [5][6] - The company is committed to enhancing its competitive edge through continuous R&D investments in core business areas [3][5] Group 3: Future Growth Strategies - The company plans to expand its feed, pig farming, and agricultural product businesses, leveraging its strategic location to explore markets in Central Asia [3][4] - Future growth will also involve potential mergers and acquisitions based on market conditions [4][6] - The company aims to diversify its business by exploring related fields such as pet feed and vaccines [7][9] Group 4: Financial Goals and Market Position - The company's operational targets for 2025 include a total revenue of 21 billion yuan, with specific goals for feed production, animal vaccines, and corn storage [7][9] - The company has opened over 70 direct sales stores and counters in the northwest and north China regions [11][12] - The company is focused on improving its market value through enhanced governance and investor communication [12][13]

Group 1 - The animal vaccine sector saw an increase of 1.28%, ranking 8th among concept sectors, with 13 stocks rising, including Reap Bio, Blue Biological, and Yongshun Biological, which rose by 6.01%, 4.42%, and 4.36% respectively [1][2] - The leading stocks in terms of net inflow of main funds were Reap Bio with a net inflow of 9.98 million yuan, followed by Tiankang Biological, Kexing Pharmaceutical, and Biological Shares with net inflows of 9.45 million yuan, 5.12 million yuan, and 1.64 million yuan respectively [2][3] - The main fund inflow ratios were led by Shunlian Biological, Kexing Pharmaceutical, and Tiankang Biological, with net inflow ratios of 7.59%, 5.97%, and 5.13% respectively [3] Group 2 - The stocks with the largest declines included *ST Xianfeng, Haili Biological, and Ronioushan, which fell by 4.97%, 0.72%, and 0.66% respectively [1][4] - The overall trend in the animal vaccine sector indicates a mixed performance, with some stocks experiencing significant gains while others faced declines [1][4] - The trading volume and turnover rates varied significantly among the stocks, with some showing high turnover rates despite negative price movements [4]